Annovis Bio Inc. released new findings from its Phase 3 early Parkinson's disease study demonstrating that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology. This subgroup represents approximately 25% of the study population and typically experiences faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer's pathology. The data reinforce the company's view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins.
This positions buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson's and Alzheimer's disease biology. The findings suggest that addressing multiple pathological proteins simultaneously may be crucial for effective treatment of neurodegenerative conditions where disease pathologies frequently coexist. The implications of these results extend beyond Parkinson's disease treatment, potentially offering a new approach to addressing cognitive decline in multiple neurodegenerative conditions.
By targeting the common underlying mechanisms of protein toxicity, buntanetap represents a shift from disease-specific treatments to broader therapeutic strategies that could benefit patients across various neurological disorders characterized by overlapping pathologies. The full press release detailing these findings is available at https://ibn.fm/CK0zo. For additional information about the company's research and development efforts, visit https://www.annovisbio.com. Investors seeking the latest news and updates relating to ANVS can access the company's newsroom at https://ibn.fm/ANVS.
